Sharechat Logo

RUA - Key Appointment of Chief of Sales and Marketing, Australia

Wednesday 13th December 2023

Text too small?

Rua Bioscience proudly announce the strategic appointment of Mr. John Sanders as the Chief of Sales and Marketing for Australia, marking a pivotal moment as he becomes the first Australian employee of Rua Bioscience.

 

Mr. Sanders, with a rich background in the cannabis sector, brings a wealth of experience to Rua Bioscience. His noteworthy three-year tenure at Cannasouth Bioscience, a NZ-based medicinal cannabis company, coupled with his extensive commercial experience in the pharmaceutical sector, including roles at Roche, Bayer, Merk and Sharp & Dome, uniquely positions him for success in this dynamic role.

 

As Rua Bioscience embarks on strategic expansion in the Australian market, Mr. Sanders will play a crucial role in overseeing sales and marketing operations from Melbourne. His appointment is a key step in our strategy to broaden our presence and reach in growing the Australian medicinal cannabis market.

 

Expressing his optimism, Paul Naske, CEO of Rua Bioscience, commented: "The appointment of John as Chief of Sales and Marketing for Australia is a significant milestone for Rua Bioscience. His impressive pharmaceutical and industry track record align seamlessly with our growth strategy in Australia. Under John’s leadership, we are confident in the success of our sales and marketing endeavours in this strategically important market”.

 

Rua Bioscience remains committed to delivering value through strategic appointments and expansion initiatives. The company looks forward to the positive impact Mr. Sanders will undoubtably bring to operations in Australia.

 

ENDS



  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

FBU - Fletcher Building Announces Director Appointment
December 23rd Morning Report
MWE - Suspension of Trading and Delisting
EBOS welcomes finalisation of First PWA
CVT - AMENDED: Bank covenant waiver and trading update
Gentrack Annual Report 2024
December 20th Morning Report
Rua Bioscience announces launch of new products in the UK
TEM - Appointment to the Board of Directors
December 19th Morning Report